NGL Fine-Chem earnings calls.

NGL Fine-Chem delivered a standout Q4 FY26 with 124.23 croreCurrent 124.23 crore. Reported change: +3 under review. revenue (+57Current reported value: 57. No comparable prior figure is available in the source record.% YoY) and 48.13 crore PATCurrent 48.13 crore PAT. Reported change: +3 under review. for FY26 (+128% YoY), marking the third consecutive quarter of operational improvement. The recovery is broad-based, driven by expanded product portfolio (45Current 45. Reported change: +25 APIs in 3 years. APIs vs 20 three years ago), Latin America market penetration gains, and improved capacity utilization following Phase 1 commissioning. EBITDA margin of 14.35%Current 14.35%. Reported change: +3 under review. expanded 769bps YoY but compressed sequentially due to geopolitical-driven freight and raw material cost pressures that could not be fully passed on under fixed-price contracts; partial price increases have been secured from Q1 FY27. Phase 2 Tarapur expansion faces a one-quarter delay to Q2 FY27 due to gas/labor shortages, with capex at 182.75 croreCurrent reported value: 182.75 crore. No comparable prior figure is available in the source record. of 210 crore total. Management targets 15-18% EBITDA margin band and expects regulated market (EU) contribution to begin FY27 with US FDA audit timing remaining uncertain. Key risks include Chinese competition maintaining price discipline and potential delays in US FDA approvals for regulated market entry.